ArticleFrontiers in allergy2026
Longitudinal basophil activation testing for assessing response to low-dose initiation, slow-escalation peanut oral immunotherapy in patients with high Ara h 2-sIgE.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peanut oral immunotherapy (pOIT) can achieve desensitization, yet patients with high peanut-sIgE may experience more adverse reactions and treatment failure. We evaluated a conservative pOIT protocol in children with high Ara h 2-sIgE (≥40 kU/L) and examined longitudinal basophil activation test (BAT) and sIgE/sIgG4 trajectories as candidate biomarkers. Methods: Thirty-two peanut-allergic children underwent pOIT, including 16 with high and 16 with lower Ara h 2-sIgE. All received low-dose initiation and slow up-dosing. Clinical outcomes, safety, and immunologic markers were evaluated longitudinally for up to 36 months. Results: Effective desensitization (≥300 mg peanut protein) was achieved in 68.8% of high-sIgE and 62.5% of lower-sIgE participants. One severe adverse event occurred in each subgroup, with no treatment-related discontinuations. Peanut and Ara h 2/6-sIgE levels rose transiently before gradually declining, whereas sIgG4 increased early, leading to a reduced sIgE/sIgG4 ratio. A ratio <50 was associated with effective desensitization. BAT responses initially increased and subsequently declined, with progressive increase in the activation threshold. Baseline BAT and sIgE were not associated with desensitization. However, BAT area under the curve (AUC) <100 was significantly associated with effective desensitization with ROC AUC of 0.784 (bootstrap 95% CI 0.536-0.983). Exploratory time-lagged analyses did not establish prospective predictive utility. Conclusions: Low-dose initiation, slow-escalation pOIT achieved effective desensitization in patients with high Ara h 2-sIgE, without treatment-related discontinuations. Longitudinal reductions in BAT and sIgE/sIgG4 ratio were associated with increased ingested dose. These exploratory biomarkers may provide adjunctive information during pOIT, but prospective validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.